Citations

Showing 10 of 108162 citations.

Primary lateral sclerosis (PLS) functional rating scale: PLS‐specific clinimetric scale
Mitsumoto, Hiroshi , Chiuzan, Codruța , Gilmore, Madison , Zhang, Yuan , Simmons, Zachary , Kisanuki, Yasushi, Zinman, Lorne , Jawdat, Omar, Sorenson, Eric J. , Floeter, Mary Kay, Filho, J. Americo M. Fernandes, Heitzman, Daragh, Fournier, Christina , Oskarsson, Björn , Heiman‐Patterson, Terry , Maragakis, Nicholas J. , Joyce, Nanette C. , Hayat, Ghazala , Nations, Sharon , Scelsa, Stephen N. , Walk, David , Elman, Lauren , Hupf, Jonathan , McHale, Brittany , group, the PLSFRS study, Sorenson, Eric, Simmons, Zachary , Oskarsson, Björn , Maragakis, Nicholas , Walk, David , Paganoni, Sabrina , Pioro, Erik P. , group, the PLSFRS study

Mayo Clinic

Muscle & Nerve | November 23, 2019 | Volume: 61 | Issue: 2 | Pages: 163-172

10.1002/mus.26765 | PMID 31758557 Get It

AbstractIntroductionOur research aim was to develop a novel clinimetric scale sensitive enough to detect disease progression in primary lateral sclerosis (PLS).MethodsA prototype of the PLS Functional Rating Scale (PLSFRS) was generated. Seventy‐seven participants with PLS were enrolled and evaluated at 21 sites that comprised the PLSFRS study group. Participants were assessed using the PLSFRS, Neuro‐Quality of Life (QoL), Schwab‐England Activities of Daily Living (ADL), and the Clinical Global Impression of Change scales. Participants completed telephone assessments at 12, 24, and 48 weeks after enrollment.ResultsThe PLSFRS demonstrated internal consistency as well as intrarater, interrater, telephone test‐retest reliability, and construct validity. Significant changes in disease progression were detected at 6 and 12 months; changes measured by the PLSFRS vs the ALSFRS‐R were significantly higher.DiscussionThe PLSFRS is a valid tool to assess the natural history of PLS in a shorter study period.
Patient Satisfaction With Providers: Do Patient Surveys Give Enough Information to Help Providers Improve Specific Behaviors
North, Frederick , Tulledge‐Scheitel, Sidna M.

Mayo Clinic

Health Services Research and Managerial Epidemiology | November 23, 2019 | Volume: 6 | Issue: No issue available | Pages: No page available

10.1177/2333392819885284 | PMID 31803794 Get It

Background: Patient satisfaction surveys ask patients specific questions about provider behavior such as whether they were satisfied with the provider’s instructions about medications or time spent with the patient. It’s unclear how responses to these surveys can help providers focus on specific behaviors to improve. Methods: In a primary care setting, we analyzed Press Ganey patient experience survey responses. We examined the 10 questions dealing with satisfaction specific to the care provider experience. We used the “Top Box” counts (counts of most favorable responses) and Top Box% (percentage of most favorable response) for categorical and continuous measures of patient satisfaction. Results: For 12 consecutive months, 652 providers of 1014 accumulated at least 300 total responses from patients for the 10 provider-related questions. Only 8 of the 652 providers had significant differences ( P < .05) in Top Box% for the 10 questions. Correlation of responses between the questions were between 0.86 and 0.96. Analysis of variance showed that 87% of the total variation in the Top Box% of the 10 questions was between providers and only 13% within providers. Factor analysis found no independent factors within the 10 questions (ie, a one factor model was sufficient; P < .0001). Conclusion: Patient survey questions appear to ask about specific provider behaviors that contribute to patient experience. However, the responses to 10 different questions are highly correlated and may not give providers or management enough statistically significant information to focus patient experience improvement efforts for individual providers.
Rapid Generation of Sustainable HER2-specific T-cell Immunity in Patients with HER2 Breast Cancer using a Degenerate HLA Class II Epitope Vaccine
Knutson, Keith L. , Block, Matthew S. , Norton, Nadine , Erskine, Courtney L. , Hobday, Timothy J. , Dietz, Allan B. , Padley, Douglas, Gustafson, Michael P. , Puglisi-Knutson, Danell, Mangskau, Toni Kay, Chumsri, Saranya , Dueck, Amylou C., Karyampudi, Lavakumar, Wilson, G. Haswell , Dueck, Amylou C. , Degnim, Amy C , Dueck, A. C. , Dietz, Allan B , Knutson, Keith L. , Mangskau, Toni K., Wilson, Glynn, Degnim, Amy C. , Norton, Nadine

Mayo Clinic

Clinical Cancer Research | November 22, 2019 | Volume: 26 | Issue: 5 | Pages: 1045-1053

10.1158/1078-0432.ccr-19-2123 | PMID 31757875 Get It

AbstractPurpose:Patients with HER2+ breast cancer benefit from trastuzumab-containing regimens with improved survival. Adaptive immunity, including cytotoxic T-cell and antibody immunity, is critical to clinical efficacy of trastuzumab. Because Th cells are central to the activation of these antitumor effectors, we reason that HER2 patients treated with trastuzumab may benefit by administering vaccines that are designed to stimulate Th-cell immunity.Patients and Methods:We developed a degenerate HER2 epitope–based vaccine consisting of four HLA class II–restricted epitopes mixed with GM-CSF that should immunize most (≥84%) patients. The vaccine was tested in a phase I trial. Eligible women had resectable HER2+ breast cancer and had completed standard treatment prior to enrollment and were disease free. Patients were vaccinated monthly for six doses and monitored for safety and immunogenicity.Results:Twenty-two subjects were enrolled and 20 completed all six vaccines. The vaccine was well tolerated. All patients were alive at analysis with a median follow-up of 2.3 years and only two experienced disease recurrence. The percent of patients that responded with augmented T-cell immunity was high for each peptide ranging from 68% to 88%, which led to 90% of the patients generating T cells that recognized naturally processed HER2 antigen. The vaccine also augmented HER2-specific antibody. Immunity was sustained in patients with little sign of diminishing at 2 years following the vaccination.Conclusions:Degenerate HLA-DR–based HER2 vaccines induce sustainable HER2-specific T cells and antibodies. Future studies, could evaluate whether vaccination during adjuvant treatment with trastuzumab-containing regimens improves patient outcomes.
Frequency of Gestational Diabetes Mellitus Reappearance or Absence during the Second Pregnancy of Women Treated at Mayo Clinic between 2013 and 2018
Enninga, Elizabeth Ann L. , Alrahmani, Layan , Leontovich, Alexey A. , Ruano, Rodrigo , Sarras, Michael P. , Egan, Aoife M. , Alrahmani, Layan , Ruano, Rodrigo , Sarras, Michael P , Enninga, Elizabeth Ann L

Mayo Clinic

Journal of Diabetes Research | November 22, 2019 | Volume: 2019 | Issue: No issue available | Pages: 1-7

10.1155/2019/9583927 | PMID 31886293 Get It

The Center for Disease Control and Prevention ranks diabetes mellitus (DM) as the seventh leading cause of death in the USA. The most prevalent forms of DM include Type 2 DM, Type 1 DM, and gestational diabetes mellitus (GDM). While the acute problem of diabetic hyperglycemia can be clinically managed through dietary control and lifestyle changes or pharmacological intervention with oral medications or insulin, long-term complications of the disease are associated with significant morbidity and mortality. These long-term complications involve nearly all organ systems of the body and share common pathologies associated with endothelial cell abnormalities. To better understand the molecular mechanisms underlying DM as related to future long-term complications following hyperglycemia, we have undertaken a study to determine the frequency that GDM did or did not occur in the second pregnancy of women who experienced GDM in their first pregnancy between 2013 and 2018 at Mayo Clinic, Rochester, MN. Within the five-year period of the study, the results indicate that 7,330 women received obstetrical care for pregnancy during the study period. Of these, 150 developed GDM in their first pregnancy and of these, 42 (28%) had a second pregnancy. Of these 42 women, 20 again developed GDM and 22 did not develop GDM in their second pregnancy within the study period. Following the occurrence of GDM in the first pregnancy, the study (1) established the number of women with and without GDM in the second pregnancy and (2) confirmed the feasibility to study diabetic metabolic memory using maternal placental tissue from GDM women. These studies represent Phase I of a larger research project whose goal is to analyze epigenetic mechanisms underlying true diabetic metabolic memory using endothelial cells isolated from the maternal placenta of women with and without GDM as described in this article.
Predictors of patient dissatisfaction at 1 and 2 years after lumbar surgery
Macki, Mohamed, Alvi, Mohammed Ali , Kerezoudis, Panagiotis , Xiao, Shujie, Schultz, Lonni, Bazydlo, Michael , Bydon, Mohamad , Park, Paul , Chang, Victor , _, _, Alvi, Mohammed Ali , _, _

Mayo Clinic

Journal of Neurosurgery: Spine | November 22, 2019 | Volume: 32 | Issue: 3 | Pages: 373-382

10.3171/2019.8.spine19260 | PMID 31756702 Get It

OBJECTIVE As compensation transitions from a fee-for-service to pay-for-performance healthcare model, providers must prioritize patient-centered experiences. Here, the authors’ primary aim was to identify predictors of patient dissatisfaction at 1 and 2 years after lumbar surgery. METHODS The Michigan Spine Surgery Improvement Collaborative (MSSIC) was queried for all lumbar operations at the 1- and 2-year follow-ups. Predictors of patients’ postoperative contentment were identified per the North American Spine Surgery (NASS) Patient Satisfaction Index, wherein satisfied patients were assigned a score of 1 (“the treatment met my expectations”) or 2 (“I did not improve as much as I had hoped, but I would undergo the same treatment for the same outcome”) and unsatisfied patients were assigned a score of 3 (“I did not improve as much as I had hoped, and I would not undergo the same treatment for the same outcome”) or 4 (“I am the same or worse than before treatment”). Multivariable Poisson generalized estimating equation models were used to report adjusted risk ratios (RR adj ). RESULTS Among 5390 patients with a 1-year follow-up, 22% reported dissatisfaction postoperatively. Dissatisfaction was predicted by higher body mass index (RR adj =1.07, p < 0.001), African American race compared to white (RR adj = 1.51, p < 0.001), education level less than high school graduation compared to a high school diploma or equivalent (RR adj = 1.25, p = 0.008), smoking (RR adj = 1.34, p < 0.001), daily preoperative opioid use > 6 months (RR adj = 1.22, p < 0.001), depression (RR adj = 1.31, p < 0.001), symptom duration > 1 year (RR adj = 1.32, p < 0.001), previous spine surgery (RR adj = 1.32, p < 0.001), and higher baseline numeric rating scale (NRS)–back pain score (RR adj = 1.04, p = 0.002). Conversely, an education level higher than high school graduation, independent ambulation (RR adj = 0.90, p = 0.039), higher baseline NRS–leg pain score (RR adj = 0.97, p = 0.013), and fusion surgery (RR adj = 0.88, p = 0.014) decreased dissatisfaction. Among 2776 patients with a 2-year follow-up, 22% reported dissatisfaction postoperatively. Dissatisfaction was predicted by a non-white race, current smoking (RR adj = 1.26, p = 0.004), depression (RR adj = 1.34, p < 0.001), symptom duration > 1 year (RR adj = 1.47, p < 0.001), previous spine surgery (RR adj = 1.28, p < 0.001), and higher baseline NRS–back pain score (RR adj = 1.06, p = 0.003). Conversely, at least some college education (RR adj = 0.87, p = 0.035) decreased the risk of dissatisfaction. CONCLUSIONS Both comorbid conditions and socioeconomic circumstances must be considered in counseling patients on postoperative expectations. After race, symptom duration was the strongest predictor of dissatisfaction; thus, patient-centered measures must be prioritized. These findings should serve as a tool for surgeons to identify at-risk populations that may need more attention regarding effective communication and additional preoperative counseling to address potential barriers unique to their situation.
microRNA overexpression in slow transit constipation leads to reduced Na V 1.5 current and altered smooth muscle contractility
Mazzone, Amelia , Strege, Peter R. , Gibbons, Simon J. , Alcaino, Constanza , Joshi, Vikram , Haak, Andrew J. , Tschumperlin, Daniel J. , Bernard, Cheryl E., Chua, Heidi K, Graham, Rondell P. , Refaey, Mona El , Mohler, Peter J. , Hayashi, Yujiro , Ördög, Tamás , Du, Peng , Farrugia, Gianrico , Ordog, Tamas , Du, Peng , Farrugia, Gianrico , Beyder, Arthur , Gibbons, S J , Graham, Rondell P , Strege, Peter R , Mazzone, Amelia , Cima, Robert R. , Larson, David W. , Calder, Stefan , Beyder, Arthur , Joshi, Vikram

Mayo Clinic

Gut | November 22, 2019 | Volume: 69 | Issue: 5 | Pages: 868-876

10.1136/gutjnl-2019-318747 | PMID 31757880 Get It

Objective This study was designed to evaluate the roles of microRNAs (miRNAs) in slow transit constipation (STC). Design All human tissue samples were from the muscularis externa of the colon. Expression of 372 miRNAs was examined in a discovery cohort of four patients with STC versus three age/sex-matched controls by a quantitative PCR array. Upregulated miRNAs were examined by quantitative reverse transcription qPCR (RT-qPCR) in a validation cohort of seven patients with STC and age/sex-matched controls. The effect of a highly differentially expressed miRNA on a custom human smooth muscle cell line was examined in vitro by RT-qPCR, electrophysiology, traction force microscopy, and ex vivo by lentiviral transduction in rat muscularis externa organotypic cultures. Results The expression of 13 miRNAs was increased in STC samples. Of those miRNAs, four were predicted to target SCN5A , the gene that encodes the Na + channel Na V 1.5. The expression of SCN5A mRNA was decreased in STC samples. Let-7f significantly decreased Na + current density in vitro in human smooth muscle cells. In rat muscularis externa organotypic cultures, overexpression of let-7f resulted in reduced frequency and amplitude of contraction. Conclusions A small group of miRNAs is upregulated in STC, and many of these miRNAs target the SCN5A-encoded Na + channel Na V 1.5. Within this set, a novel Na V 1.5 regulator, let-7f, resulted in decreased Na V 1.5 expression, current density and reduced motility of GI smooth muscle. These results suggest Na V 1.5 and miRNAs as novel diagnostic and potential therapeutic targets in STC.
An Age-Based Approach to Anterior Shoulder Instability in Patients Under 40 Years Old: Analysis of a US Population
Leland, Devin P. , Bernard, Christopher D. , Keyt, Lucas K. , Krych, Aaron J. , Dahm, Diane L., Sanchez-Sotelo, Joaquin, Krych, Aaron J , Sánchez‐Sotelo, Joaquín , Camp, Christopher L.

Mayo Clinic

The American Journal of Sports Medicine | November 22, 2019 | Volume: 48 | Issue: 1 | Pages: 56-62

10.1177/0363546519886861 | PMID 31756127 Get It

Background: While a large volume of literature has focused on risk factors for anterior shoulder instability, the rates of recurrence are inconsistent and require additional population-based epidemiologic data. Purpose/Hypothesis: The purpose was to report the effect of patient age on the number of instability events before physician consultation, rate of surgical stabilization, recurrent instability, and progression to osteoarthritis in patients <40 years old with anterior shoulder instability, utilizing an established US geographic population. We hypothesized that younger patients would be more likely to experience multiple episodes of instability before evaluation, undergo surgery, and experience recurrent instability after surgical intervention. Study Design: Descriptive epidemiologic study. Methods: An established geographic database of more than 500,000 patients was used to identify patients <40 years of age with anterior shoulder instability between 1994 and 2016. Medical records were reviewed to obtain patient characteristics, history, imaging, surgical details, and outcomes. Patients were divided into 5 groups based on age (≤15, 16-20, 21-25, 26-30, and 31-40 years) at initial instability. Comparative analysis was performed to identify differences between groups. Results: The study population consisted of 654 patients with a mean follow-up of 11.1 years (range, 2.0-25.2 years). This resulted in 118 patients (18%) ≤15 years of age at initial instability; 250 (38%), 16 to 20 years; 110 (17%), 21 to 25 years; 80 (12%), 26 to 30 years; and 96 (15%), 31 to 40 years. Of patients ≤15 years old at initial instability 47% had 3+ instability events, compared with 12% of patients aged 31 to 40 years ( P < .001). At 10 years of follow-up, patients ≤15 and 16 to 20 years old demonstrated the highest recurrent instability rates of 38.8% and 47.1% after nonoperative management, respectively. Patients 16 to 20 years old demonstrated the highest rates of both surgical intervention (40.4%) and recurrence after surgery (24.8%). Patients 31 to 40 years of age were significantly more likely to develop clinically symptomatic osteoarthritis (15.6%) than all other age groups. Conclusion: In a US epidemiologic population of patients <40 years old, the rate of recurrent anterior shoulder instability was roughly one-third after initial physician consultation. Younger patients, particularly those ≤15 and 16 to 20 years of age, were more likely to have experienced multiple instability events at the time of initial evaluation, require surgery, and experience recurrent instability compared with older patients. For every year of decrease in age at initial instability, the risk of recurrent instability or surgical intervention after physician consultation increased by 4.1% and 2.8%, respectively.
Targeting DNA Methylation for Treating Triple-Negative Breast Cancer
Yu, Jia , Zayas, Jacqueline , Qin, Bo , Wang, Liewei

Mayo Clinic

Pharmacogenomics | November 22, 2019 | Volume: 20 | Issue: 16 | Pages: 1151-1157

10.2217/pgs-2019-0078 | PMID 31755366 Get It

The cost‐effectiveness of pharmacotherapy and lifestyle intervention in the treatment of obesity
Lee, Minyi , Lauren, Brianna N. , Zhan, Tiannan , Choi, Jin , Klebanoff, Matthew J. , Dayyeh, Barham Abu, Taveras, Elsie M. , Kaplan, Lee M. , Hur, Chin , Abu Dayyeh, Barham, Corey, Kathleen E.

Mayo Clinic

Obesity Science & Practice | November 22, 2019 | Volume: 6 | Issue: 2 | Pages: 162-170

10.1002/osp4.390 | PMID 32313674 Get It

SummaryBackgroundThe Food and Drug Administration has approved several pharmacotherapies for the treatment of obesity. This study assesses the cost‐effectiveness of six pharmacotherapies and lifestyle intervention for people with mild obesity (body mass indices [BMIs] 30 to 35).MethodsA microsimulation model was constructed to compare seven weight loss strategies plus no treatment: intensive lifestyle intervention, orlistat, phentermine, phentermine/topiramate, lorcaserin, liraglutide, and semaglutide. Weight loss, quality‐of‐life scores, and costs were estimated using clinical trials and other published literature. Endpoints included costs, quality‐adjusted life years (QALYs), and incremental cost‐effectiveness ratios (ICERs) with a willingness‐to‐pay (WTP) threshold of $100 000/QALY. Results were analysed at 1‐, 3‐, and 5‐year time horizons.ResultsAt each of the three follow‐up periods, phentermine was the cost‐effective strategy, with ICERs of $46 258/QALY, $20 157/QALY, and $17 880/QALY after 1, 3, and 5 years, respectively. Semaglutide was the most effective strategy in the 3‐ and 5‐year time horizons, with total QALYs of 2.224 and 3.711, respectively. However, the ICERs were prohibitively high at $1 437 340/QALY after 3 years and $576 931/QALY after 5 years. Deterministic and probabilistic sensitivity analyses indicated these results were robust.ConclusionsPhentermine is the cost‐effective pharmacologic weight‐loss strategy. Although semaglutide is the most effective, it is not cost‐effective because of its high price.
Medical Student Perspectives on LGBTQ Health
Christensen, Julie A. , Hunt, Travis, Jerpbak, Christine, Hunt, Travis J , Elsesser, Steven A.

Mayo Clinic

PRiMER | November 22, 2019 | Volume: 3 | Issue: No issue available | Pages: No page available

10.22454/primer.2019.288724 | PMID 32537598 Get It

Introduction: Lesbian, gay, bisexual, transgender, and queer (LGBTQ) community members experience adverse health outcomes at higher rates than non-LGBTQ individuals. We examined the impact of student demographics as well as gender and sexuality didactic instruction on the attitudes of first-year medical students toward LGBTQ patients. Methods: In January 2017, 255 first-year students at an urban allopathic medical school participated in a gender and sexuality health curriculum. We assessed student attitudes regarding LGBTQ patients using anonymous pre- and postintervention surveys. Each item was measured on a 5-point Likert scale. Results: Of 255 possible respondents, we received 244 responses to the preintervention survey (95.7% response rate) and 253 to the postintervention survey (99.2% response rate). Participants were predominantly white (66.8%), heterosexual (94.7%), and cisgender (100%). Respondents who identified as LGBQ were significantly (P&lt;.05) more likely than heterosexual students to agree with the following preintervention statements, among others: (1) Discordance between birth sex and gender is a natural human phenomenon, (2) When meeting a patient for the first time, I feel comfortable asking what pronoun they use, (3) I am able to empathize with the life experience of an LGB/T patient, (4) I am motivated to seek out opportunities to learn more about LGBTQ-specific health care issues. Statistically significant changes in attitudes between time points are seen in 4 out of 15 items. Conclusion: A focused gender and sexuality curriculum appears to impact medical student attitudes regarding LGBTQ patients. Furthermore, recruitment of LGBTQ-identifying medical students may translate into improved workforce motivation to provide health care for LGBTQ patients.